Figure 2
Treatment of Tg2576 mice with amylin or its analog pramlintide reduces the amyloid burden and improves their learning and memory. At 9 months of age, Tg2576 mice were treated with intraperitoneal injection of phosphate-buffered saline (PBS), amylin (200 pg kg−1) or pramlintide (200 pg kg−1) daily for 10 weeks (n=8 per group) (Supplementary Table S2). Both amylin- and pramlintide-treated mice had reduced concentrations of (a) Aβ1-42 (measured as pg per 10 μg brain protein) and (b) Aβ1–40 in the brain compared with PBS-treated controls. (c) Both amylin- and pramlintide-treated mice had increased concentrations of Aβ1–42 (pg ml−1) in CSF, but (d) neither treatment significantly affected the concentration of Aβ1–40. (e) Compared with PBS treatment, both amylin- and pramlintide-treated mice exhibited improved cognition by showing increased percentage of alternation in the Y maze test. Mean±s.e. was used with *P<0.05.
